蒽环类药物对乳腺癌患者血清ER、VEGF-C、VEGFR-3及E-cadherin影响研究  

Study on effect of anthracyclines on VEGF-C,VEGFR-3,ER and E-cadherin in serum of patients with breast cancer

作　　者：陈道宝[1] 陈波[1] 杨红健[1] 俞星飞[1] 封伟亮[1] 

机构地区：[1]浙江省肿瘤医院乳腺外科,浙江杭州310022

出　　处：《中国生化药物杂志》2015年第6期137-139,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨蒽环类药物对乳腺癌患者血清ER、VEGF-C、VEGFR-3及E-cadherin的影响。方法收集收治的乳腺癌患者43例,按用药不同随机分为实验组22例和对照组21例。两组分别按实验方案基于治疗,治疗结束后对患者血清VEGF-C、VEGFR-3水平以及乳腺组织ER、E-cadherin水平进行检测。结果与对照组相比,实验组患者VEGF-C、VEGFR-3水平较低(P<0.05);ER水平较低(P<0.05);E-cadherin水平较高(P<0.05)。结论蒽环类药物能显著降低乳腺癌患者ER、VEGF-C、VEGFR-3水平,升高E-cadherin水平,对临床有指导意义。Objective To investigate effect of anthracyclines of VEGF-C, VEGFR-3, ER and E-cadherin in serum of patients with breast cancer.Methods 43 patients with breast cancer were selected and randomly divided into experimental group and control group, 40 cases in each group.According to the experimental program based on the treatment, serum VEGF-C, VEGFR-3 levels and breast tissue ER and E-cadherin were detected after the end of the treatment.Results Compared with the control group, VEGF-C, VEGFR-3 levels of the experiment group were lower（ P〈0.05）,ER level was lower（P〈0.05） and E-cadherin level was higher（P〈0.05）.Conclusion the ER, VEGFR-3 and VEGF-C levels in breast cancer patients can significantly decrease the E-cadherin level, and it has a guiding significance for clinical.

关 键 词：蒽环类药物 乳腺癌 ER VEGF-C VEGFR-3 E-CADHERIN 

分 类 号：R737.9[医药卫生—肿瘤]